Table 4. Treatment of the primary tumour against the treatment of SP tumours.
| Primary tumour | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Breast-conserving surgery | Chemotherapy | Radiotherapy | Hormone therapy | ||||||
| SP | No | Yes | No | Yes | No | Yes | No | Yes | |
| (n = 299) | (n = 446) | (n = 585) | (n = 160) | (n = 248) | (n = 497) | (n = 585) | (n = 160) | ||
| Surgery | No | 3%* | 1%* | 4% | 1% | 3%* | 2%* | 3% | 1% |
| (n = 34) | |||||||||
| Yes | 39%* | 56%* | 73% | 22% | 32%* | 63%* | 73% | 23% | |
| (n = 711) | |||||||||
| Chemotherapy | No | 34% | 44% | 64%* | 14%* | 29% | 50% | 60%* | 19%* |
| (n = 551) | |||||||||
| Yes | 8% | 13% | 13%* | 9%* | 6% | 15% | 16%* | 5%* | |
| (n = 194) | |||||||||
| Radiotherapy | No | 33%* | 19%* | 39% | 13% | 28%* | 25%* | 37%* | 15%* |
| (n = 373) | |||||||||
| Yes | 9%* | 38%* | 38% | 10% | 7%* | 41%* | 39%* | 9%* | |
| (n = 372) | |||||||||
| Hormone therapy | No | 27% | 39% | 51% | 15% | 22% | 45% | 53%* | 14%* |
| (n = 477) | |||||||||
| Yes | 15% | 18% | 26% | 7% | 13% | 20% | 24%* | 10%* | |
| (n = 268) | |||||||||
* indicates a significant difference. Abbreviations: SP = second primary.